LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! Here I am again! This week has been full of very interesting and positive news. The momentum continues! Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Phase 2 Trial: SECuRE Interim Results for mCRPC Radioligand Therapy​
  The SECuRE trial is investigating 67Cu-SAR-bisPSMA, a radioligand therapy showing promising interim results in a challenging population of patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). In an analysis of nine participants, 66.7% achieved a PSA50 response, while 33.3% reached the PSA80 threshold. The safety profile remains favorable, with no new renal toxicity signals or additional toxicities reported when the treatment is combined with enzalutamide. One striking case study featured a 64-year-old patient who achieved an undetectable PSA level and no visible metastatic disease on scans after three treatment cycles.
  ​
• Phase 1/2 Trial: SL-28 Donor Cell Therapy for Solid Tumors​
  ​SL-28 is a novel donor cell therapy known as Leukocyte-Tells that does not require genetic modification or immune-marker matching between the donor and patient. A Phase 1/2 trial currently underway in Australia has documented a significant case involving a 79-year-old man with prostate cancer and bone spread who failed to respond to hormone drugs. After receiving SL-28 monotherapy, the patient experienced a complete response with his PSA dropping to 0.1 ng/mL and the disappearance of all metastases. Notably, this response was achieved without the need for standard androgen deprivation therapy (ADT), and the patient remained disease-free eight months post-treatment.
  ​
• Phase 1/2 Trial: ANDROMEDA Study of AZD9750 AR Degrader​
  The ANDROMEDA trial is a first-in-human study evaluating AZD9750, a novel androgen receptor (AR) PROTAC designed for men with mCRPC. Unlike traditional inhibitors that only block the receptor’s activity, this therapy recruits cellular machinery to completely degrade the AR protein, potentially overcoming common resistance mechanisms. The trial uses a modular design to assess AZD9750 both as a monotherapy and in combination with saruparib, a selective PARP1 inhibitor that exploits DNA repair vulnerabilities.
  ​
• Phase 1/2 Trial: GSK5471713 for Resistant Prostate Cancer​
  GSK5471713 is an investigational small-molecule androgen receptor (AR) degrader being tested in a first-in-human trial for patients who have exhausted standard hormonal and chemotherapy options. The therapeutic rationale is to eliminate the AR protein entirely via the cell’s ubiquitin–proteasome system, rather than just blocking ligand binding. This approach aims to reduce both ligand-dependent and ligand-independent signaling, which is critical in castration-resistant disease where the AR pathway is often hypersensitized. The ongoing study is currently defining the recommended Phase 2 dose while monitoring safety and preliminary antitumor activity.
  ​
• Phase 1 Trial: A-CAR032 Armored CAR-T Therapy​
  A new Phase 1 trial is evaluating A-CAR032, a CAR-T cell therapy that targets STEAP2, a protein found on over 85% of prostate cancer cells from early to late stages. To overcome the immune-suppressive barriers of the tumor environment, these T cells are “armored” to block TGF-β signals, which normally weaken immune attacks. The treatment involves collecting a patient’s T cells, engineering them with the STEAP2 receptor and TGF-β armor, and infusing them back after chemotherapy to allow the cells to expand and target the cancer.
  ​
• Phase 1 Trial: STEAP1 CAR‑T Plus Enzalutamide​
  This clinical trial investigates a second-generation CAR-T therapy targeting STEAP1, a protein highly abundant on advanced prostate cancer cells but limited in healthy tissues. Preclinical research showed that a single dose of these engineered cells led to rapid tumor shrinkage and curative-like activity in mouse models mimicking widespread metastatic disease. The study combines this immunotherapy with enzalutamide, based on laboratory evidence suggesting that blocking the androgen receptor can stress cancer cells, making them more vulnerable to immune attack.
  ​
• NADIR Model: A Prognostic Tool for Early Treatment Stratification​
  The NADIR model is a simple mathematical framework developed to help clinicians predict which patients with metastatic hormone-sensitive prostate cancer (mHSPC) will achieve a deep PSA response (≤0.2 ng/mL) by six months. By utilizing baseline data such as PSA levels, age, and tumor size, the model categorizes patients into three risk groups, with the best group showing a 92 percent success rate in reaching the target PSA. This early prediction is critical because patients in the best group had an 80 percent survival rate at four years, compared to only 56 percent in the worst group, allowing doctors to adjust treatment intensity much sooner.
  ​

Preclinical Research & Reviews

• Stem Cell Breakthrough for Scalable Helper T Cell Therapies​
  Researchers have achieved a major advance by developing a method to produce functional helper T cells from stem cells in a controlled laboratory environment. Helper T cells are essential because they act as “conductors,” alerting and coordinating killer T cells to provide a stronger, more durable immune response. By fine-tuning the Notch signaling pathway during development, this method enables the mass production of “off-the-shelf” cell therapies, which could significantly reduce the high costs and long delays associated with current personalized CAR-T manufacturing.
  ​
• DrugCLIP: AI-Driven Acceleration of Drug Discovery​
  ​DrugCLIP is a new AI system developed at Tsinghua University that identifies potential medicines millions of times faster than traditional simulations. By converting proteins and molecules into math vectors, the system can screen massive libraries—such as 500 million compounds against 10,000 proteins in a single day—without the need for slow computer shape-fitting. The tool has already successfully identified binders for tough targets like TRIP12, a protein linked to cancer growth that was previously considered difficult to target.

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max